Literature DB >> 17189043

Transcranial brain parenchyma sonography in movement disorders: state of the art.

Uwe Walter1, Stefanie Behnke, Jens Eyding, Ludwig Niehaus, Thomas Postert, Günter Seidel, Daniela Berg.   

Abstract

The present paper summarizes recommendations on transcranial sonography (TCS) application in neurodegenerative diseases, resulting from a consensus meeting of the European Society of Neurosonology and Cerebral Hemodynamics. TCS of distinct infra- and supratentorial brain structures detects characteristic changes in several movement disorders, such as abnormal hyperechogenicity of substantia nigra (SN) in Parkinson's disease and of lenticular nucleus in dystonia, Wilson's disease and atypical Parkinsonian disorders. In healthy adults, the TCS finding of marked SN hyperechogenicity indicates a subclinical functional impairment of the nigrostriatal dopaminergic system. The finding of marked SN hyperechogenicity in combination with normal lenticular-nucleus echogenicity discriminates idiopathic Parkinson's disease from multiple-system atrophy and progressive supranuclear palsy with a positive predictive value of more than 90%. As TCS is a quick and noninvasive method, using the same duplex-ultrasound machines as for investigation of intracranial vessels, applicable even in agitated patients, this method has a great potential to be more widely used.

Entities:  

Mesh:

Year:  2007        PMID: 17189043     DOI: 10.1016/j.ultrasmedbio.2006.07.021

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  46 in total

1.  Transcranial sonography on Parkinson's disease and essential tremor in a Chinese population.

Authors:  Wei-Feng Luo; Ying-Chun Zhang; Yu-Jing Sheng; Jun-Chu Fang; Chun-Feng Liu
Journal:  Neurol Sci       Date:  2011-12-11       Impact factor: 3.307

Review 2.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

3.  Sonographic detection of bilateral striopallidodentate calcinosis.

Authors:  Christos Krogias; Saskia Meves; Martin Schoellhammer; Ralf Gold; Juergen Andrich
Journal:  J Neurol       Date:  2009-02-26       Impact factor: 4.849

4.  Basal ganglia hyperechogenicity does not distinguish between patients with primary dystonia and healthy individuals.

Authors:  Johann Hagenah; Inke R König; Charlotte Kötter; Günter Seidel; Christine Klein; Norbert Brüggemann
Journal:  J Neurol       Date:  2010-11-02       Impact factor: 4.849

Review 5.  Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

6.  Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein.

Authors:  Uwe Walter; Rike Witt; Alexander Wolters; Matthias Wittstock; Reiner Benecke
Journal:  J Neural Transm (Vienna)       Date:  2011-05-31       Impact factor: 3.575

7.  Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.

Authors:  Norbert Brüggemann; Johann Hagenah; Kaili Stanley; Christine Klein; Cuiling Wang; Deborah Raymond; Laurie Ozelius; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2011-02-10       Impact factor: 10.338

8.  Transcranial sonography image characteristics in different Parkinson's disease subtypes.

Authors:  Ai Yan Sheng; Ying Chun Zhang; Yu Jing Sheng; Cai Shan Wang; Ying Zhang; Hua Hu; Wei Feng Luo; CHun-Feng LIu
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

9.  Transcranial sonography in spinocerebellar ataxia type 2.

Authors:  Milija Mijajlović; Natasa Dragasević; Elka Stefanova; Igor Petrović; Marina Svetel; Vladimir S Kostić
Journal:  J Neurol       Date:  2008-05-07       Impact factor: 4.849

10.  Transcranial sonography for diagnosis of Parkinson's disease.

Authors:  Sabine Mehnert; Iris Reuter; Karsten Schepp; Peter Maaser; Erwin Stolz; Manfred Kaps
Journal:  BMC Neurol       Date:  2010-01-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.